Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) ended June with £10 million in cash, helped by an oversubscribed £4.9 million fundraise. Its lead drug POLB 001 is set for Phase 2a trials, with interim data due in summer 2026, alongside an oral GLP-1 study.
Solvonis Therapeutics PLC (LSE:SVNS) says the Awakn Life Sciences acquisition has expanded its pipeline in addiction and psychiatry. Lead program SVN-001 is in a Phase 3 trial for alcohol use disorder, while SVN-002 has FDA clearance that may help it skip early-stage trials.
EMV Capital (AIM:EMVC) now manages over £100 million in assets across more than 70 portfolio companies. Recent highlights include acquiring Destiny Pharma’s IP, a 2.5x return at Martlet Capital, and growth from US health tech and Scandinavian deep tech.
Light Science Technologies Holdings PLC (AIM:LST) secured BS 8670 accreditation for its Passive Fire Protection division. Its £28 million pipeline includes £0.5 million of new UK orders, and the group expects to turn profitable in 2026.
Coinsilium Group Limited (AQSE:COIN, OTCQB:CINGF) boosted its Bitcoin treasury to 182 BTC, lifting digital assets on its balance sheet to £6 million. The company expects value from upcoming token launches, starting with Yellow Network’s $YELLOW token, alongside growth in blockchain venture building.
Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.
